Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article.
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.
Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M. Suzawa K, et al. Among authors: somwar r. JCO Precis Oncol. 2019;3:10.1200/PO.19.00011. doi: 10.1200/PO.19.00011. Epub 2019 May 10. JCO Precis Oncol. 2019. PMID: 31157314 Free PMC article. No abstract available.
Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.
Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA. Offin M, et al. JCO Precis Oncol. 2018;2:10.1200/PO.18.00126. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. JCO Precis Oncol. 2018. PMID: 30957057 Free PMC article. No abstract available.
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M. Vojnic M, et al. Among authors: somwar r. J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1. J Thorac Oncol. 2019. PMID: 30831205 Free PMC article.
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.
Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, Kris MG, Hellmann MD, Li BT, Somwar R, Solit DB, Berger MF, Arcila M, Riely GJ, Ladanyi M. Yu HA, et al. Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12. Clin Cancer Res. 2018. PMID: 29530932 Free PMC article.
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations.
Li GG, Somwar R, Joseph J, Smith RS, Hayashi T, Martin L, Franovic A, Schairer A, Martin E, Riely GJ, Harris J, Yan S, Wei G, Oliver JW, Patel R, Multani P, Ladanyi M, Drilon A. Li GG, et al. Clin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23. Clin Cancer Res. 2017. PMID: 28011461 Free PMC article.
Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma.
Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK, Mittal V, Somwar R, Stiles BM, Du YN. Wang D, et al. Oncotarget. 2016 Jun 28;7(26):39957-39969. doi: 10.18632/oncotarget.9554. Oncotarget. 2016. PMID: 27220886 Free PMC article.
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA. Drilon A, et al. Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16. Clin Cancer Res. 2016. PMID: 26673800 Free PMC article.
Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.
Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H, Varmus HE. Somwar R, et al. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16375-80. doi: 10.1073/pnas.1113554108. Epub 2011 Sep 19. Proc Natl Acad Sci U S A. 2011. PMID: 21930909 Free PMC article.
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W. Chmielecki J, et al. Sci Transl Med. 2011 Jul 6;3(90):90ra59. doi: 10.1126/scitranslmed.3002356. Sci Transl Med. 2011. PMID: 21734175 Free PMC article.
55 results
Jump to page
Feedback